Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2483-2492

  Fu, Xinping ^a   Rivera, Armando ^a   Tao, Lihua ^a   Zhang, Xiaoliu ^a  

^a University of Houston   (United States)

Author keywords

v 3 integrin; chimeric antigen receptor; echistatin; T cells; tumor neovasculature

Indexed keywords

ECHISTATIN CONTAINING CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; NANOPARTICLE; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD VESSEL; CANCER INHIBITION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; SPLEEN CELL; T LYMPHOCYTE; TUMOR BLEEDING; TUMOR CELL; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

CHIMERIC ANTIGEN RECEPTOR; ECHISTATIN; T CELLS; TUMOR NEOVASCULATURE; ΑVΒ3 INTEGRIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; BLOOD VESSELS; CELL LINE; CELL LINE, TUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTANT CHIMERIC PROTEINS; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ANTIGEN; T-LYMPHOCYTES;

EID: 84883808117     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28269     Document Type: Article

References (41)

1. van der Merwe PA, Davis SJ,. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 2003; 21: 659-84.
2. Kammertoens T, Blankenstein T,. Making and circumventing tolerance to cancer. Eur J Immunol 2009; 39: 2345-53.
3. Jena B, Dotti G, Cooper LJ,. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; 116: 1035-44.
4. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009; 106: 3360-5.
5. Davies DM, Maher J,. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells. Arch Immunol Ther Exp (Warsz) 2010; 58: 165-78.
6. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-24.
7. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-102.
8. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-33.
9. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-70.
10. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19: 620-6.
11. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007; 15: 825-33.
12. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12: 6106-15.
13. Hsu C, Hughes MS, Zheng Z, et al. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005; 175: 7226-34.
14. Quintarelli C, Vera JF, Savoldo B, et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110: 2793-802.
15. Terakura S, Yamamoto TN, Gardner RA, et al. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 2012; 119: 72-82.
16. Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113: 6392-402.
17. Kumar CC, Nie H, Rogers CP, et al. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J Pharmacol Exp Ther 1997; 283: 843-53.
18. Cai W, Chen X,. Anti-angiogenic cancer therapy based on integrin alpha(v)beta(3) antagonism. Anticancer Agents Med Chem 2006; 6: 407-28.
19. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, et al. Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins. J Biol Chem 1999; 274: 37809-14.
20. Fu X, Tao L, Rivera A, et al. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One 2010; 5: e11867.
21. Ahmed N, Ratnayake M, Savoldo B, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 2007; 67: 5957-64.
22. Morita S, Kojima T, Kitamura T,. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 1063-6.
23. Frankel TL, Burns WR, Peng PD, et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 2010; 184: 5988-98.
24. Kerkar SP, Sanchez-Perez L, Yang S, et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother 2011; 34: 343-52.
25. Hieken TJ, Farolan M, Ronan SG, et al. Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 1996; 63: 169-73.
26. Duan X, Jia SF, Zhou Z, et al. Association of alpha(v)beta(3) integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis 2004; 21: 747-53.
27. Gong W, Zhang GM, Liu Y, et al. IFN-gamma withdrawal after immunotherapy potentiates B16 melanoma invasion and metastasis by intensifying tumor integrin alpha(v)beta(3) signaling. Int J Cancer 2008; 123: 702-8.
28. Liu Y, Mounkes LC, Liggitt HD, et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997; 15: 167-73.
29. Cox D, Brennan M, Moran N,. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 9: 804-20.
30. Kurtz L, Kao L, Newman D, et al. Integrin alphaIIbbeta3 inside-out activation: an in situ conformational analysis reveals a new mechanism. J Biol Chem 2012; 287: 23255-65.
31. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66: 10995-1004.
32. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822-6.
33. Smolarczyk R, Cichon T, Graja K, et al. Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. Acta Biochim Pol 2006; 53: 801-5.
34. Greish K,. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010; 624: 25-37.
35. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-13.
36. Curti BD, Urba WJ, Alvord WG, et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res 1993; 53: 2204-7.
37. Rofstad EK, Ruud EB, Mathiesen B, et al. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin Cancer Res 2010; 16: 936-45.
38. Jain RK,. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1: 241-63.
39. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-121.
40. Hofmann M, McCormack E, Mujic M, et al. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia 2009; 11: 812-22.
41. Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012; 7: 383-8.